Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 4/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3886029 | 0.84 | BPTF (0.45) | HTR2CHTR2AHTR2B | |
| SCHEMBL3887869 | 0.84 | BPTF (0.45) | HTR2CHTR2AHTR2B | |
| SCHEMBL3886031 | 0.84 | BPTF (0.45) | HTR2CHTR2AHTR2B | |
| SCHEMBL3886033 | 0.84 | BPTF (0.45) | HTR2CHTR2AHTR2B | |
| SCHEMBL2971715 | 0.79 | CHRNB2 (0.38) | — | |
| SCHEMBL2961660 | 0.79 | CHRNB2 (0.31) | — | |
| SCHEMBL11763350 | 0.78 | CHRNB2 (0.40) | HTR2CHTR2AHTR2B | |
| SCHEMBL2963438 | 0.78 | PNMT (0.31) | — | |
| SCHEMBL1047199 | 0.77 | HTR2C (0.42) | HTR2CHTR2AHTR2BSIGMAR1 | |
| SCHEMBL29613747 | 0.77 | HTR2C (0.42) | HTR2CHTR2AHTR2BSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022012534-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS | 广州费米子科技有限责任公司 | 2022-01-20 | — | — | WO | disclosed |
| US-7550500-B2 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-20060014964-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | DUNCIA JOHN V | 2006-01-19 | — | — | US | disclosed |
| US-6960666-B2 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20040209876-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | DUNCIA JOHN V (US) | 2004-10-21 | — | — | US | disclosed |
| US-6784200-B2 | SUCH AS N-3-(CIS-2,3,3A,4,9,9A-HEXAHYDRO-1H-BENZ(F)ISOINDOL-2-YL)-N-PROP-1-YL-N'-3 -ACETYLPHENYLUREA FOR PREVENTION OF INFLAMMATORY DISEASES (ASTHMA AND ALLERGIES) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-31 | — | — | US | disclosed |
| US-20040006084-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | DUNCIA JOHN V (US) | 2004-01-08 | — | — | US | disclosed |
| US-6586446-B1 | Chemotaxic cytokine agonists or antagonists such as N(3-acetylphlenyl)-N'-(-2-((-3-((4-fluorophenyl)methyl)-8 -azabicyclo(3.2.1)oct-8-yl)methyl)-(2R)-1-cyclohexyl)urea, used as antiinflammatory agents for asthma or allergies | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209876-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | CCR1, CCR3, CCR10 | ADRA2A 231/4885HTR2C 833/4885HTR2A 1189/4885 |
| US-20040006084-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | CCR1, CCR3, CCR10 | ADRA2A 231/4885HTR2C 833/4885HTR2A 1189/4885 |
| US-20060014964-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | CCR3, CCR1, NR1I3 | ADRA2A 247/4885HTR2C 612/4885HTR2A 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.